Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Camlin Fine Sciences Limited is an India‑headquartered specialty chemicals manufacturer producing antioxidants, aroma ingredients (vanillin/ethyl vanillin), value‑added blends, and performance chemicals with global manufacturing and application laboratories, serving food, feed, nutraceutical, fragrance and industrial end markets across 80+ countries.
Q3 FY26 consolidated revenue was Rs. 4,572 million (up ~6% YoY) while adjusted EBITDA contracted to Rs. 307 million (6.7% margin) and PAT turned negative due to exceptional items, FX adjustments and higher operating costs; management highlighted tariff dynamics, inventory phasing and acquisition costs as primary drivers of near‑term margin pressure.
Vanillin is a major strategic lever: Camlin Fine Sciences delayed some sales to capture tariff benefits, expects improved realizations following US tariff reductions, and targets 4,000 tonnes of Vanillin in FY27 — a potential material revenue and margin driver if channel stocks and tariffs evolve favorably.
The company is actively reshaping its footprint — acquiring Vinpai to enter natural functional ingredients and scaling Vitafor in animal nutrition while pursuing liquidation of loss‑making European and Chinese subsidiaries to stop cash burn, representing simultaneous portfolio expansion and pruning.
Near‑term operational risks include a fire at a Brazil plant (insurer survey ongoing, book loss ~Rs. 32.7 crore reported), tariff sensitivity in Vanillin realizations, and structural pricing pressure in straights; management expects these to be transitory but they materially affect quarterly performance.
Chemicals & Petrochemicals
Specialty Chemicals
1,997 Cr
High Risk
-30.9
40.0
—
1.9
234.00
96.30
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Camlin Fine Sciences Ltd (CAMLINFINE) is currently trading at 103.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Camlin Fine Sciences Limited is an India‑headquartered specialty chemicals manufacturer producing antioxidants, aroma ingredients (vanillin/ethyl vanillin), value‑added blends, and performance chemicals with global manufacturing and application laboratories, serving food, feed, nutraceutical, fragrance and industrial end markets across 80+ countries. Q3 FY26 consolidated revenue was Rs. 4,572 million (up ~6% YoY) while adjusted EBITDA contracted to Rs. 307 million (6.7% margin) and PAT turned negative due to exceptional items, FX adjustments and higher operating costs; management highlighted tariff dynamics, inventory phasing and acquisition costs as primary drivers of near‑term margin pressure. Vanillin is a major strategic lever: Camlin Fine Sciences delayed some sales to capture tariff benefits, expects improved realizations following US tariff reductions, and targets 4,000 tonnes of Vanillin in FY27 — a potential material revenue and margin driver if channel stocks and tariffs evolve favorably. The company is actively reshaping its footprint — acquiring Vinpai to enter natural functional ingredients and scaling Vitafor in animal nutrition while pursuing liquidation of loss‑making European and Chinese subsidiaries to stop cash burn, representing simultaneous portfolio expansion and pruning. Near‑term operational risks include a fire at a Brazil plant (insurer survey ongoing, book loss ~Rs. 32.7 crore reported), tariff sensitivity in Vanillin realizations, and structural pricing pressure in straights; management expects these to be transitory but they materially affect quarterly performance.
Over the past 52 weeks, Camlin Fine Sciences Ltd has traded between a low of ₹96.30 and a high of ₹234.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Camlin Fine Sciences Ltd has a market capitalization of approximately 1,996.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Camlin Fine Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -30.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,996.84 Cr, Camlin Fine Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Camlin Fine Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Camlin Fine Sciences Ltd is -30.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company announced its Q1 FY27 results on August 11, 2026, for the quarter ended June 30, 2026.
CFSL’s draft OPAS offers €3.60 per Vinpai share, the same price as the November 2025 block acquisition.
CFSL has disclosed an OPAS price of €3.60 per Vinpai share, the same as the block acquisition price.
It filed a draft simplified cash tender offer (OPAS) document with France’s AMF to acquire Vinpai shares it does not already hold.
Discovery themes featuring this stock
Bearish
4
Neutral
7
Bullish
3
Bearish
27
Neutral
7
Bullish
12
Bearish
23
Neutral
0
Bullish
9
Bearish
4
Neutral
7
Bullish
3
Bearish
4
Neutral
7
Bullish
3
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
143.25 | 2,005 Cr | 22.67 | 1.47 | 0.69 | 3.60 | 5.52 | 3.06 | ||
103.80 | 1,997 Cr | -30.85 | 1.92 | 0.00 | 1.18 | 3.77 | 0.03 | ||
730.00 | 1,841 Cr | 43.43 | 3.75 | 0.33 | 8.01 | 9.02 | 6.42 | ||
524.95 | 1,820 Cr | 342.13 | 2.74 | 0.09 | 0.50 | 4.36 | 0.45 | ||
617.00 | 1,755 Cr | 790.55 | 37.43 | 0.00 | 2.90 | 5.84 | 1.53 | ||
339.95 | 1,743 Cr | 32.74 | 5.32 | 0.86 | 14.93 | 18.30 | 12.72 | ||
437.00 | 1,735 Cr | 56.42 | 9.56 | 0.12 | 16.46 | 20.87 | 14.38 | ||
| Median: 7 Co. | — | 437.00 | 1,820 Cr | 43.43 | 3.75 | 0.12 | 3.60 | 5.84 | 3.06 |
